Видео ютуба по тегу Speaker: Geoffrey Oxnard

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC
Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC
Dr. Geoffrey R. Oxnard on When to Change EGFR TKIs
Dr. Geoffrey R. Oxnard on When to Change EGFR TKIs
Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer
Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer
Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib
Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib
How Do We Make EGFR Inhibitors Work Better for Patients
How Do We Make EGFR Inhibitors Work Better for Patients
Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
Friends of Cancer Research Virtual Meeting: Do changes in ctDNA reflect response to treatment?
Friends of Cancer Research Virtual Meeting: Do changes in ctDNA reflect response to treatment?
Lung Cancer - interview with Geoff Oxnard, MD, at ASCO 2012
Lung Cancer - interview with Geoff Oxnard, MD, at ASCO 2012
Conquering Lung Cancer Oxnard
Conquering Lung Cancer Oxnard
Interpretation of NSCLC Plasma Genotyping Results
Interpretation of NSCLC Plasma Genotyping Results
GRACEcastUC080_Lung_Dr Oxnard Are Patients or Payers Objecting to Repeat Biopsy
GRACEcastUC080_Lung_Dr Oxnard Are Patients or Payers Objecting to Repeat Biopsy
CCGA: plasma cfDNA lung cancer screening
CCGA: plasma cfDNA lung cancer screening
How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow?
How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow?
Final Thoughts
Final Thoughts
Acquired Resistance to Osimertinib in T790M-Positive NSCLC
Acquired Resistance to Osimertinib in T790M-Positive NSCLC
Cancer detecting and locating: cell-free DNA
Cancer detecting and locating: cell-free DNA
Impact of COVID-19 on scientific research and treating patients
Impact of COVID-19 on scientific research and treating patients
Immunotherapy in the Frontline and as Part of Combinations for NSCLC
Immunotherapy in the Frontline and as Part of Combinations for NSCLC